Anti-C1q autoantibodies from systemic lupus erythematosus patients activate the complement system via both the classical and lectin pathways.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical Immunology

• Publication date

  2015-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clim.2015.06.014PMID 26148903
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anti-C1q autoantibodies from active lupus nephritis patients could inhibit the clearance of apoptotic cells and complement classical pathway activation mediated by C1q in vitro.

  2014cited by this paper
• Deposition of the lectin pathway of complement in renal biopsies of lupus nephritis patients.

  2013cited by this paper
• Targeting the complement system in systemic lupus erythematosus and other diseases.

  2013cited by this paper
• Innate immune processes in lupus erythematosus.

  2013cited by this paper
• Pathogenesis and significance of glomerular C4d deposition in lupus nephritis: activation of classical and lectin pathways.

  2013cited by this paper
• Identification of a major linear C1q epitope allows detection of systemic lupus erythematosus anti-C1q antibodies by a specific peptide-based enzyme-linked immunosorbent assay.

  2012cited by this paper
• The Complement System in Cryoglobulinemia

  2012cited by this paper
• Significance of glomerular activation of the alternative pathway and lectin pathway in lupus nephritis

  2011cited by this paper
• Nucleosomes and C1q bound to glomerular endothelial cells serve as targets for autoantibodies and determine complement activation.

  2011cited by this paper
• Complement activation by (auto-) antibodies.

  2011cited by this paper
• INITIATION OF THE ALTERNATIVE PATHWAY OF COMPLEMENT BY IMMUNE COMPLEXES IS DEPENDENT ON N GLYCANS IN IgG ANTIBODIES

  2011cited by this paper
• Membrane attack by complement: the assembly and biology of terminal complement complexes

  2011cited by this paper
• Anti-C1q autoantibodies do not correlate with the occurrence or severity of experimental lupus nephritis.

  2010cited by this paper
• Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways.

  2009cited by this paper
• Complement activation and inhibition: a delicate balance.

  2009cited by this paper
• Anti‐C1q antibodies: association with nephritis and disease activity in systemic lupus erythematosus

  2009cited by this paper
• C1q Differentially Modulates Phagocytosis and Cytokine Responses during Ingestion of Apoptotic Cells by Human Monocytes, Macrophages, and Dendritic Cells1

  2009cited by this paper
• The alternative complement pathway revisited

  2008cited by this paper
• Autoantibodies against complement C1q in acute post-streptococcal glomerulonephritis.

  2008cited by this paper
• Initiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodies.

  2008cited by this paper
• Autoantibodies against Complement C1q Specifically Target C1q Bound on Early Apoptotic Cells1

  2008cited by this paper
• Role of complement and complement regulators in the removal of apoptotic cells.

  2008cited by this paper
• Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies.

  2007cited by this paper
• Mechanisms of Disease: the complement system and the pathogenesis of systemic lupus erythematosus

  2006cited by this paper
• Mannose binding lectin binds IgM to activate the lectin complement pathway in vitro and in vivo

  2006cited by this paper
• High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis.

  2006cited by this paper
• Activation of the lectin pathway in murine lupus nephritis.

  2005cited by this paper
• Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus

  2004cited by this paper
• Opsonization with C1q and Mannose-Binding Lectin Targets Apoptotic Cells to Dendritic Cells1

  2004cited by this paper
• Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes.

  2004cited by this paper
• Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus – relationship with disease activity and renal involvement

  2003cited by this paper
• Pathogenesis of systemic lupus erythematosus

  2003cited by this paper
• Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome.

  2003cited by this paper
• Direct binding of C1q to apoptotic cells and cell blebs induces complement activation

  2002cited by this paper
• Human IgA Activates the Complement System Via the Mannan-Binding Lectin Pathway1

  2001cited by this paper
• Complement. First of two parts.

  2001cited by this paper
• Successful treatment of patients with systemic lupus erythematosus by immunoadsorption with a C1q column: a pilot study.

  2001cited by this paper
• Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity

  2001cited by this paper
• C1q and Mannose Binding Lectin Engagement of Cell Surface Calreticulin and Cd91 Initiates Macropinocytosis and Uptake of Apoptotic Cells

  2001cited by this paper
• A Hierarchical Role for Classical Pathway Complement Proteins in the Clearance of Apoptotic Cells in Vivo

  2000cited by this paper
• Links between complement abnormalities and systemic lupus erythematosus.

  2000cited by this paper
• Complement-dependent Clearance of Apoptotic Cells by Human Macrophages

  1998cited by this paper
• Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies

  1998cited by this paper
• Deposition of antibodies to the collagen-like region of C1q in renal glomeruli of patients with proliferative lupus glomerulonephritis.

  1997cited by this paper
• Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

  1997cited by this paper
• Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus.

  1995cited by this paper
• Subclass Distribution of IgA and IgG Antibodies Against Clq in Patients with Rheumatic Diseases

  1995cited by this paper
• Cardiogenic hypertrophic osteoarthropathy.

  1992cited by this paper
• IgG and IgA autoantibodies to C1q in systemic and renal diseases.

  1992cited by this paper
• IgG autoantibodies to C1q do not detectably influence complement activation in vivo and in vitro in systemic lupus erythematosus

  1992cited by this paper
• Autoantibodies to the collagen-like region of C1Q deposit in glomeruli via C1Q in immune deposits.

  1991cited by this paper
• Evidence for the presence of autoantibodies to the collagen-like portion of C1q in systemic lupus erythematosus.

  1988cited by this paper
• C1q solid-phase radioimmunoassay: evidence for detection of antibody directed against the collagen-like region of C1q in sera from patients with systemic lupus erythematosus.

  1987cited by this paper
• Clq solid phase radioimmunoassay evidence for detection of antibody directed against the collagen like region of clq in sera from patients with systemic lupus erythematosus

  1987cited by this paper
• The 1982 revised criteria for the classification of systemic lupus erythematosus.

  1982cited by this paper

• Anti-C1q antibodies: a biomarker for diagnosis and management of lupus nephritis. A narrative review

  2024cites this paper
• Integrative analysis of the association between circadian rhythm and lupus nephritis

  2023cites this paper
• Management of Lupus Nephritis: New Treatments and Updated Guidelines

  2023cites this paper
• Epitope-Specific Anti-C1q Autoantibodies in Systemic Lupus Erythematosus

  2022cites this paper
• Clinical Importance of C1q Antibodies in Systemic Lupus Patients With and Without Nephritis

  2022cites this paper
• Comparison of circulating miR-148a and miR-126 with autoantibodies as biomarkers of lupus nephritis in patients with SLE

  2022cites this paper
• Anti‐C1q autoantibodies from systemic lupus erythematosus patients enhance CD40–CD154‐mediated inflammation in peripheral blood mononuclear cells in vitro

  2022cites this paper
• Systematic identification of key extracellular proteins as the potential biomarkers in lupus nephritis

  2022cites this paper
• Endothelial Dysfunction in Systemic Lupus Erythematosus and Systemic Sclerosis: A Common Trigger for Different Microvascular Diseases

  2022cites this paper
• The role of anti-complement therapy in lupus nephritis.

  2022cites this paper
• Disease criteria of systemic lupus erythematosus (SLE); the potential role of non-criteria autoantibodies

  2022cites this paper
• Impact of Autoantibodies to Complement Components on the Disease Activity in SLE.

  2021cites this paper
• Genetic and transcriptomic analyses support a switch to lytic phase in Epstein Barr virus infection as an important driver in developing Systemic Lupus Erythematosus.

  2021cites this paper
• Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice

  2021cites this paper
• Autoantibodies against complement component C1q in systemic lupus erythematosus

  2021cites this paper
• High frequency of concurrent anti-C1q and anti-dsDNA but not anti-C3b antibodies in patients with Lupus Nephritis

  2021cites this paper
• IFN-I Mediates Dysfunction of Endothelial Progenitor Cells in Atherosclerosis of Systemic Lupus Erythematosus

  2020cites this paper
• A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE

  2020cites this paper
• Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy

  2020cites this paper
• Autoantibodies specific for C1q, C3b, β2-glycoprotein 1 and annexins may amplify complement activity and reduce apoptosis-mediated immune suppression.

  2020cites this paper
• The Concurrent Anti-C1q and Anti-dsDNA but not Anti-C3b Antibodies as Potent Biomarkers for Lupus Nephritis prediction

  2020cites this paper
• Anti-C1q Antibodies as Occurring in Systemic Lupus Erythematosus Could Be Induced by an Epstein-Barr Virus-Derived Antigenic Site

  2019cites this paper
• Utilization of Biomarkers in Lupus Nephritis.

  2019cites this paper
• Ficolin-3 Deficiency Is Associated with Disease and an Increased Risk of Systemic Lupus Erythematosus

  2019cites this paper
• The Immunopathology of Complement Proteins and Innate Immunity in Autoimmune Disease

  2019cites this paper
• Complement regulation and kidney diseases: recent knowledge of the double-edged roles of complement activation in nephrology

  2018cites this paper
• Inhibition of Immune Complex Complement Activation and Neutrophil Extracellular Trap Formation by Peptide Inhibitor of Complement C1

  2018cites this paper
• Precision medicine in lupus nephritis: can biomarkers get us there?

  2018cites this paper
• Antibodies targeting circulating protective molecules in lupus nephritis: Interest as serological biomarkers.

  2018cites this paper
• Cathepsin S inhibition suppresses autoimmune‐triggered inflammatory responses in macrophages

  2017cites this paper
• Anti‐C1q autoantibodies from patients with systemic lupus erythematosus induce C1q production by macrophages

  2017cites this paper
• Correlation of Serum Soluble Interleukin-7 Receptor and Anti-C1q Antibody in Patients with Systemic Lupus Erythematosus

  2016cites this paper
• Overview of Laboratory Testing and Clinical Presentations of Complement Deficiencies and Dysregulation.

  2016cites this paper
• Advances in the diagnosis and classification of systemic lupus erythematosus

  2016cites this paper
• Autoantibodies in SLE: Specificities, Isotypes and Receptors

  2016cites this paper
• Clinical and pathologic considerations of the qualitative and quantitative aspects of lupus nephritogenic autoantibodies: A comprehensive review.

  2016cites this paper